🔗 Share this article

While the US undertakes sweeping adjustments to its vaccination guidelines, one figure has surfaced in a surprising turn: Dr. Tracy Beth Høeg, a Danish American sports physician and public health researcher who rose to prominence by expressing skepticism about COVID-19 vaccinations throughout the pandemic and has focused upon potential fatalities after COVID-19 immunization in her brief tenure at the FDA.

Scheduled Shifts to Pediatric Immunization Schedule

Health officials had intended to reveal major revisions to the childhood immunization program recently, synchronizing the US with the Danish immunization schedule, according to reports – a substantial departure that would put the US out of alignment with many the world with insufficient data for benefit. The planned update has been pushed back until the next year.

In place of the director of the vaccine center, Tracy Beth Høeg is set to present at the event. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to run the center this calendar year.

A New Direction at the Regulatory Body

The acting appointment could signify a tighter collaboration between the pharmaceutical and biologics divisions as Dr. Høeg and Dr. Prasad solidify control at the agency – and it suggests a increased emphasis upon rolling back long-standing vaccines at the FDA.

Høeg has frequently advocated for discontinuing specific pediatric shot schedules in the US so as to align more in line with Denmark, a country with nationalized medicine and a population approximately the population of the state of Wisconsin.

To date public appearances, she has kept her attention on immunizations – typically the domain of Dr. Prasad, chief of the FDA’s CBER – instead of drug regulation.

Concerns Over Qualifications

The appointee has no apparent track record in pharmaceutical research, regulation or management, which has been typical for past directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a top consultant to the commissioner and CBER since earlier this year.

“She doesn’t seem to have the requisite experience” for leading the CDER, remarked Jonathan Howard. “She’s never run a randomized controlled trial. She is not versed in leading a large organization. She has no expertise in industry regulation.”

Past directors of the center would “be deeply familiar with laws and regulations and the research of medication creation”, noted Dr. Janet Woodcock. “Clearly, she lacks the type of experience that prior appointees who headed the center have had.”

CDER has an vast portfolio at the FDA, Woodcock stated.

“Many people just focuses on the innovative therapies, but the generic program authorizes a multitude of generic drugs. There is also a biologic copycat branch, non-prescription drug unit and other areas, and all of those have to be looked after,” she said. “The responsibility you don’t keep your eye on, that is the part that I always told people is going to cause problems.”

Additionally, a substantial management element to the role, which manages over 5,000 personnel. “It is a huge management job, if you perform it correctly,” she added.

Official Statement and Contentious Programs

Regarding concerns about Dr. Høeg's credentials and whether this selection signifies increased cooperation among FDA leaders on immunizations, a press secretary responded that the “questions stem from incorrect assumptions”.

“Her resume aligns with the duties of her position,” the spokesperson said, pointing to the time Høeg spent counseling the agency head on “medication safety and regulatory science, including predictive safety algorithms and vaccine surveillance”.

As acting director, Høeg assumes responsibility for the agency head's controversial priority voucher program, a disputed rapid medication authorization process that reportedly worried her predecessors. “How are these drugs being chosen for this voucher program? Who takes the calls?” Dr. Howard asked. “There’s a lot of lack of transparency going on at the agency right now.”

In general, he stated, “the Food and Drug Administration looks to be trending towards more relaxed oversight of pharmaceuticals, with the exception of vaccines.”

Documented History on Immunizations

With vaccines, Dr. Høeg has a more established, if problematic, past, Howard have noted. She authored a research paper using non-validated crowd-sourced reports to determine the frequency of heart inflammation after COVID-19 vaccination. She counseled the state of Florida surgeon general Dr. Joseph Ladapo, who reportedly have modified findings to imply Covid vaccinations are riskier than they are.

Included in her “desired changes” for the current administration encompassed altering guidelines for novel immunizations and ending “optional” vaccines, she said after the election on a audio program. At the agency, Høeg has reportedly proposed barring teenage boys from receiving COVID-19 vaccinations.

“She is an all-around ideologue who begins with her conclusions and works backwards to fit the data in a highly disingenuous, dishonest way,” Dr. Howard argued.

Gaining Influence and a “Revenge Tour”

Dr. Høeg became part of other skeptics, {like|